BACKGROUND: Elevated levels of oxidized phospholipids (OxPLs) on apolipoprotein B-100 particles (OxPL/apoB) are associated with cardiovascular disease and predict new cardiovascular events. Elevated lipoprotein (a) [Lp(a)] levels are a risk factor for cardiovascular disease in whites and also in blacks if they carry small apolipoprotein(a) [apo(a)] isoforms. The relationship of OxPL/apoB levels to race/ethnicity, cardiovascular risk factors, and apo(a) isoforms is not established. METHODS AND RESULTS: OxPL/apoB levels were measured in 3481 subjects (1831 black, 1047 white, and 603 Hispanic subjects) in the Dallas Heart Study and correlated with age, sex, cardiovascular risk factors, and Lp(a) and apo(a) isoforms. Significant differences in OxPL/apoB levels were noted among racial/ethnic subgroups, with blacks having the highest levels compared with whites and Hispanics (P<0.001 for each comparison). OxPL/apoB levels generally did not correlate with age, sex, or risk factors. In the overall cohort, OxPL/apoB levels strongly correlated with Lp(a) (r=0.85, P<0.001), with the shape of the relationship demonstrating a "reverse L" shape for log-transformed values. The highest correlation was present in blacks, followed by whites and Hispanics; was dependent on apo(a) isoform size; and became progressively weaker with larger isoforms. The size of the major apo(a) isoform (number of kringle type IV repeats) was negatively associated with OxPL/apoB (r=-0.49, P<0.001) and Lp(a) (r=-0.61, P<0.001) regardless of racial/ethnic group. After adjustment for apo(a) isoform size, the relationship between OxPL/apoB and Lp(a) remained significant (r=0.67, P<0.001). CONCLUSIONS: OxPL/apoB levels vary according to race/ethnicity, are largely independent of cardiovascular risk factors, and are inversely associated with apo(a) isoform size. The association of OxPL with small apo(a) isoforms, in which a similar relationship is present among all racial/ethnic subgroups despite differences in Lp(a) levels, may be a key determinant of cardiovascular risk.
BACKGROUND: Elevated levels of oxidized phospholipids (OxPLs) on apolipoprotein B-100 particles (OxPL/apoB) are associated with cardiovascular disease and predict new cardiovascular events. Elevated lipoprotein (a) [Lp(a)] levels are a risk factor for cardiovascular disease in whites and also in blacks if they carry small apolipoprotein(a) [apo(a)] isoforms. The relationship of OxPL/apoB levels to race/ethnicity, cardiovascular risk factors, and apo(a) isoforms is not established. METHODS AND RESULTS: OxPL/apoB levels were measured in 3481 subjects (1831 black, 1047 white, and 603 Hispanic subjects) in the Dallas Heart Study and correlated with age, sex, cardiovascular risk factors, and Lp(a) and apo(a) isoforms. Significant differences in OxPL/apoB levels were noted among racial/ethnic subgroups, with blacks having the highest levels compared with whites and Hispanics (P<0.001 for each comparison). OxPL/apoB levels generally did not correlate with age, sex, or risk factors. In the overall cohort, OxPL/apoB levels strongly correlated with Lp(a) (r=0.85, P<0.001), with the shape of the relationship demonstrating a "reverse L" shape for log-transformed values. The highest correlation was present in blacks, followed by whites and Hispanics; was dependent on apo(a) isoform size; and became progressively weaker with larger isoforms. The size of the major apo(a) isoform (number of kringle type IV repeats) was negatively associated with OxPL/apoB (r=-0.49, P<0.001) and Lp(a) (r=-0.61, P<0.001) regardless of racial/ethnic group. After adjustment for apo(a) isoform size, the relationship between OxPL/apoB and Lp(a) remained significant (r=0.67, P<0.001). CONCLUSIONS: OxPL/apoB levels vary according to race/ethnicity, are largely independent of cardiovascular risk factors, and are inversely associated with apo(a) isoform size. The association of OxPL with small apo(a) isoforms, in which a similar relationship is present among all racial/ethnic subgroups despite differences in Lp(a) levels, may be a key determinant of cardiovascular risk.
Authors: Lidia S Szczepaniak; Pamela Nurenberg; David Leonard; Jeffrey D Browning; Jason S Reingold; Scott Grundy; Helen H Hobbs; Robert L Dobbins Journal: Am J Physiol Endocrinol Metab Date: 2004-08-31 Impact factor: 4.310
Authors: Rudy Guerra; Zhaoxia Yu; Santica Marcovina; Ronald Peshock; Jonathan C Cohen; Helen H Hobbs Journal: Circulation Date: 2005-03-21 Impact factor: 29.690
Authors: Rajat Deo; Amit Khera; Darren K McGuire; Sabina A Murphy; Januario de P Meo Neto; David A Morrow; James A de Lemos Journal: J Am Coll Cardiol Date: 2004-11-02 Impact factor: 24.094
Authors: Kenneth R Wilund; Liqing Yu; Fang Xu; Gloria L Vega; Scott M Grundy; Jonathan C Cohen; Helen H Hobbs Journal: Arterioscler Thromb Vasc Biol Date: 2004-10-28 Impact factor: 8.311
Authors: H G Kraft; A Lingenhel; S Köchl; F Hoppichler; F Kronenberg; A Abe; V Mühlberger; D Schönitzer; G Utermann Journal: Arterioscler Thromb Vasc Biol Date: 1996-06 Impact factor: 8.311
Authors: D J Moliterno; E V Jokinen; A R Miserez; R A Lange; J E Willard; E Boerwinkle; L D Hillis; H H Hobbs Journal: Arterioscler Thromb Vasc Biol Date: 1995-07 Impact factor: 8.311
Authors: E J Schaefer; S Lamon-Fava; J L Jenner; J R McNamara; J M Ordovas; C E Davis; J M Abolafia; K Lippel; R I Levy Journal: JAMA Date: 1994-04-06 Impact factor: 56.272
Authors: Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss Journal: J Lipid Res Date: 2010-08-16 Impact factor: 5.922
Authors: Corey A Scipione; Sera E Sayegh; Rocco Romagnuolo; Sotirios Tsimikas; Santica M Marcovina; Michael B Boffa; Marlys L Koschinsky Journal: J Lipid Res Date: 2015-10-16 Impact factor: 5.922
Authors: Leticia Castillo; Anand Rohatgi; Colby R Ayers; Andrew W Owens; Sandeep R Das; Amit Khera; Darren K McGuire; James A de Lemos Journal: J Interferon Cytokine Res Date: 2010-05 Impact factor: 2.607